Q1 2018: Challenging start to 2018 and a focus on accelerated commercial execution

Highlights and significant events in the first quarter

  • Ole Søgaard Andersen appointed interim CEO
  • Probi’s major customer in North America, which introduced a destocking program in the second half of 2017, has now resumed purchasing
  • Long-term development agreement signed with Cilag, a member of the Johnson & Johnson Family of Companies, regarding an OTC probiotic product
  • Major success in a positive clinical trial for a new probiotic concept in bone health and osteoporosis

Financial overview

MSEK    Q1 2018    Q1 2017 Full-year 2017
Net sales 119.2 187.4 612.2
Net sales growth, constant currency, % -33.7% 111.1% 38.2%
Gross margin, % 42.0% 50.9% 45.4%
EBITDA 17.2 62.4 157.3
EBITDA margin, % 14.4% 33.3% 25.7%
Operating profit (EBIT) 4.4 48.7 104.1
Net income 3.3 43.1 69.1
Earnings per share before and after dilution, SEK 0.29 3.79 6.06
Share price on closing day, SEK 438.40 419.00 340.00
Market cap on closing day 4,995.2 4,774.1 3,874.0
See note 5 for definitions of ratios not defined according to IFRS and note 4 for adjustments made to Q1 2017

Invitation to Teleconference
Date: 2 May 2018
Time: 10:00 a.m.
Phone: +46 8 50 55 64 53
Participants from Probi: Jörn Andreas, CFO

The presentation is available at www.probi.com and www.financialhearings.com

Ole Søgaard Andersen, CEO:, Phone: +46 46 286 89 40, E-mail: ole.sogaard.andersen@probi.com
Jörn Andreas, CFO: Phone: +46 46 286 89 41, E-mail: jorn.andreas@probi.com

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on 2 May 2018. This a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

About Probi
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four sites, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. probi.com


About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.


Documents & Links